Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial - Orban, Tihamer; Bundy, Brian; Becker, Dorothy J; DiMeglio, Linda A; Gitelman, Stephen E; Goland, Robin; Gottlieb, Peter A; Greenbaum, Carla J; Marks, Jennifer B; Monzavi, Roshanak; Moran, Antoinette; Raskin, Philip; et al. (The Lancet (British edition), 2011)
Keywords: Abatacept; Adolescent; Adult; Allergies; Autoimmunity; Biological and medical sciences; blood serum; c-peptide; Child; Clinical trials; Diabetes; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - physiopathology; Diabetes. Impaired glucose tolerance; Double-Blind Method; Embargoes & blockades; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; General aspects; Hepatitis; human resources; Humans; Immunoconjugates - adverse effects; Immunoconjugates - immunology; Immunoconjugates - therapeutic use; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Infectious diseases; insulin-dependent diabetes mellitus; Insulin-Secreting Cells - physiology; Internal Medicine; intravenous injection; Male; Medical sciences; National Institutes of Health; neutropenia; patients; Peptides; randomized clinical trials; Randomized Controlled Trials as Topic; Rheumatoid arthritis; T-lymphocytes; T-Lymphocytes - immunology; United States; Young Adult; United States; Endocrinopathy; Human; Immunopathology; Patient; Autoimmune disease; Randomized controlled trial; Immunomodulator; Medicine; Abatacept; Age of onset; Costimulation; Type 1 diabetes; Modulation; Double blind study; Clinical trial; Fusion protein